Study of FTY720 in Patients With Uveitis

Novartis logo

Novartis

Status and phase

Withdrawn
Phase 2

Conditions

Acute Noninfectious Posterior, Intermediate, or Pan Uveitis

Treatments

Drug: FTY720
Drug: Oral Corticosteroid

Study type

Interventional

Funder types

Industry

Identifiers

NCT01791192
2011-004160-30 (EudraCT Number)
CFTY720D2205

Details and patient eligibility

About

This study will assess the safety, tolerability, and efficacy of FTY720 in patients with acute, noninfectious intermediate, posterior and pan uveitis

Sex

All

Ages

18 to 60 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Acute noninfectious posterior, intermediate, or pan uveitis
  • Vitreous haze score of 1+ or more in the study eye at screening and baseline visits

Exclusion criteria

  • Vaso-occlusive vasculitis involving the retinal macula
  • Behçet's uveitis
  • Patients requiring corticosteroid or another systemic immunosuppressive medication for any other disease (e.g., asthma or some other autoimmune disease) that would contraindicate tapering (topical steroids permitted)
  • Other protocol defined inclusions and/or exclusions may apply.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

0 participants in 2 patient groups

FTY720
Experimental group
Description:
Fingolimod
Treatment:
Drug: FTY720
Oral Corticosteroid
Active Comparator group
Description:
Oral Corticosteroid
Treatment:
Drug: Oral Corticosteroid

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems